Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Highly-sensitive tumour test under development:

This article was originally published in Clinica

Executive Summary

Stem cell company Nexell Therapeutics has begun a two-year, multicentre study of a monoclonal antibody-based column for tumour cell enrichment, which forms the basis of a laboratory test for individual tumour cells. The test, which will be developed with the aid of a $535,000 grant from the US National Institutes of Health, will be used to detect breast, prostate and lung cancer metastases, said Irvine, California-based Nexell. Preclinical studies showed a sensitivity of one cell per 100 million blood cells, said the company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel